8 results about "Actinoplanes sp." patented technology

The invention discloses an actinoplanes strain and application thereof. In a first aspect of the disclosure, there is provided an actinoplanes strain, which may be a strain MN311411 having a preservation number of GDMCC No: 64167, or a strain having at least 98.65% identity with 16S rRNA of strain MN311411, or a strain having at least 98.65% identity with the 16S rRNA sequence set forth in SEQ ID NO: 1, and / or a strain having at least 95% average nucleotide identity with the genome of strain MN311411. The embodiment of the invention discloses a novel strain. The strain or a product based on the strain has a good effect of preventing and treating soil-borne plant diseases and insect pests such as root-knot nematodes and the like.

The invention discloses an actinomycete lipopeptide compound extracted from actinomycetes blue gray. The structure of the actinomycete lipopeptide compound is selected from one of the following structures. When the concentration of the actinomycetes lipopeptide compound extracted from the actinomycetes blue gray, especially the compound 5, is 20 [mu] mol / L, aggregation and migration of inflammatory cells in intestinal tracts of zebra fish can be significantly reduced, which indicates that the actinomycetes lipopeptide compound has an obvious anti-inflammatory effect. Therefore, the actinomycete lipopeptide compound can be used as a medicine for treating the inflammatory bowel disease.

The invention belongs to the field of medicinal chemistry, and discloses an artificially prepared gene knockout actinomycete SZF-217, a metabolite and application of the gene knockout actinomycete SZF-217 in anti-inflammation, and the preservation number of the actinomycete is CCTCC (China Center for Type Culture Collection) NO: M20242799. According to the present invention, the Orf40 gene in S.lividans SBT18 is knocked out by the applicant to obtain the artificially prepared gene knockout actinomycetes Streptomyces sp.SZF-217, the strain can produce a series of new compounds feitonemycin A-F, and the compound B has significant anti-inflammatory activity, and can be used for preparing immune disease drugs.

The invention discloses a dynamic regulation and control system and method for actinomycete gene expression and application. According to the invention, a dynamic regulation element for actinomycete gene expression is designed, a gene sequential expression dynamic regulation system suitable for actinomycetes is constructed based on the dynamic regulation element, and a plurality of target spots on a DNA sequence which is designed in advance and arranged in series are subjected to sequential single-base editing through a single-base editing enzyme ABE8e to finally target a promoter 35box sequence of the actinomycete gene. Finally, the expression regulation of the target gene in the actinomycetes is realized by activating or suppressing the promoter. According to the present invention, the number / length of the series Fuze-like sequence can be preset so as to control the expression time of the gene in the way of actinomycete antibiotic synthesis and the like;

The present invention relates to Actinomycetales strains for the improved formation of acarbose. Provided are Actinomycetales strains which are engineered to overexpress dTDP-D-glucose-4,6-dehydratase (AcbB) and / or uridyltransferase (GtaB). Also provided are Actinomycetales strains which are engineered to have a reduced or absent expression of the small carbohydrate binding protein (Cgt) and / or a reduced or absent expression of genes which are essential for carotenoid synthesis. Also provided are tools, methods and means to generate these strains.

This invention discloses a high-yield S-type amino acid ester imine reductase mutant, its preparation method, and its applications. The wild-type imine reductase is derived from actinomycetes. Actinomadura welshii By using directed evolution, the active site was modified to obtain imine reductase mutants with high activity, stereoselectivity, and (S)-2-((4-methoxyphenyl)amino)-2-phenylacetic acid methyl ester yield. The mutants are D98G / M122L / W216V, D98G / M122L / W216V / L15Y, D98G / M122L / W216V / L15Y / A120V, and D98G / M122L / W216V / L15Y / A120V / V124L / T238A. This invention enables the efficient synthesis of (S)-2-((4-methoxyphenyl)imino)-2-phenylacetic acid methyl ester from inexpensive (trans)-2-((4-methoxyphenyl)amino)-2-phenylacetic acid methyl ester, which is beneficial for the industrial synthesis and application of (S)-2-((4-methoxyphenyl)amino)-2-phenylacetic acid methyl ester.

The application discloses a method for enhancing actinomycin production by enhancing expression of an actinomycin in-vivo target protein APASM_1807. The method comprises the following steps: enhancing expression of the actinomycin in-vivo target protein APASM_1807 by using a strong promoter kasOp* in Actinocatenulum ramosum ATCC 31280, and obtaining a high-yield actinomycin mutant strain HQG-02. Compared with a starting strain, the high-yield strain HQG-02 obtained by the method has a fermentation yield increased by 66.5%, and a laboratory shake flask fermentation level reaches 76.6 mg / L.

The invention belongs to the technical field of animal bifidobacterium subsp. Lactis, and particularly relates to an animal bifidobacterium subsp. Lactis WLP90 and application thereof in preparation of a preparation for relieving obesity. The bifidobacterium animalis subsp. Lactis has the performance of targeted inhibition of actinomyces chlamydoides, Enterobacter cancerogenus and Alloscedobacterium animalis, can effectively inhibit pancrelipase, stimulate intestinal cells to generate glucagon-like peptide-1, can effectively improve diseases of obese mice, and can be used for preparing a preparation for relieving obesity.